Cargando…
P001 Safety, tolerability, and efficacy of 1 month of atomoxetine plus oxybutynin in obstructive sleep apnoea
INTRODUCTION: Single-night studies with noradrenergic and anti-muscarinics have recently been shown to improve upper-airway function and reduce obstructive sleep apnoea (OSA) severity. This study aimed to determine the safety, tolerability, and efficacy profile of longer-term use of different doses...
Autores principales: | Aishah, A, Loffler, K, Tonson, B, Mukherjee, S, Adams, R, Altree, T, Ainge-Allen, H, Yee, B, Grunstein, R, Taranto-Montemurro, L, Carberry, J, Eckert, D |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10109098/ http://dx.doi.org/10.1093/sleepadvances/zpab014.050 |
Ejemplares similares
-
O001 Reboxetine reduces obstructive sleep apnea severity: a randomized trial
por: Altree, T, et al.
Publicado: (2021) -
Efficacy of atomoxetine plus oxybutynin in the treatment of obstructive sleep apnea with moderate pharyngeal collapsibility
por: Schweitzer, Paula K., et al.
Publicado: (2022) -
The Combination of Betahistine and Oxybutynin Increases Respiratory Control Sensitivity (Loop Gain) in People with Obstructive Sleep Apnea: A Randomized, Placebo-Controlled Trial
por: Messineo, Ludovico, et al.
Publicado: (2022) -
P002 Targeted non-CPAP combination therapy resolves obstructive sleep apnoea
por: Aishah, A, et al.
Publicado: (2021) -
Long-term atomoxetine-oxybutynin combination use may be beneficial for the prevention of obstructive sleep apnea
por: Chen, Tien-Yu, et al.
Publicado: (2021)